Immunogenicity and predictive factors of hepatitis B vaccination with Fendrix® in chronic kidney disease patients
Bibliographic Data
| ID | 22079761 |
|---|---|
| Authors | Cristina Hernán-García (0000-0002-4365-3197, Universidad de Valladolid), Daniel Leonardo Sánchez-Carmona (0009-0002-2833-2114, Hospital Clínico Universitario de Valladolid, corresponding author), Lucía Czestochowa Mateo-Otero (Hospital Universitario Río Hortega), V Fernández Espinilla (0009-0000-7146-2059, Universidad de Valladolid), Virginia Fernández-Espinilla, Paula Andrea Rodriguez-Ducuara (Hospital Clínico Universitario de Valladolid), Javier Castrodeza (0009-0009-9529-7647, Universidad de Valladolid), José Javier Castrodeza-Sanz, Camino Prada‐García (0000-0002-2487-9350, Universidad de Valladolid), Camino Prada-García |
| Year | 2025 |
| Volume | 13 |
| Pages | 1523733-1523733 |
| Publication date | 2025-03-27 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2025.1523733 |
| PMID | 40213424 |
| OpenAlex | W4408902297 |
| Language | EN |
| References cited | 16 |
Hepatitis B virus (HBV) infection and chronic kidney disease (CKD) pose major global health challenges. CKD patients face a heightened risk of HBV infection, worsening their prognosis. This study evaluated the immune response to hepatitis B vaccination in CKD patients, the persistence of antibodies, and factors influencing vaccine efficacy. A retrospective study was conducted on 173 CKD patients (2014–2019) receiving routine vaccination at the Hospital Clínico Universitario de Valladolid, Spain. (ZIP Code:47003) Patients were immunized with Fendrix ® on a 0-1-2-6-month schedule, and verbal informed consent was obtained. A protective response was defined as Anti-HBs >10 IU/L, and a robust response as >100 IU/L. Overall, 90.8% achieved a protective response. Age was not a significant predictor ( p = 0.137) between non-responders and protective or robust responders. 32.95% of patients died during follow-up. A robust response at the end of vaccination cycle was associated with higher antibody titers at 12 months ( p = 0.002) but not at 24 ( p = 0.550) or 36 months ( p = 0.739). Kaplan–Meier analysis estimated median antibody duration as 26.5 months (Anti-HBs > 10 IU/L) and 25.4 months (Anti-HBs > 100 IU/L). A delay in vaccination compared to the recommended schedule was observed (one-sample Wilcoxon test, p < 0.001). Fendrix ® effectively induces protective immunity in CKD patients, but a robust early response does not ensure long-term persistence. The decline in antibody levels suggests the need for booster doses and periodic antibody monitoring to optimize long-term protection. Suboptimal vaccination adherence may reflect the inherent complexities of real-world clinical practice
Antibody · Antibody titer · Hepatitis B · Hepatitis B virus · Immune system · Immunity · Immunization · Immunogenicity · Kidney disease · Titer · Vaccination · Vaccination schedule · Virus · Hepatitis B Virus Studies · Hepatitis C virus research · Medicine · Vaccine Coverage and Hesitancy · Immunology · Internal Medicine
| Highly cited | No |
|---|